Did Neurocept use biomarkers (e.g., amyloid PET, tau, CSF) as primary endpoints unlike aducanumab/lecanemab?
Executive summary
Available sources do not report that a company or product named “Neurocept” ran clinical trials using amyloid PET, tau imaging, or CSF biomarkers as primary endpoints; the search returns consumer supplement press pieces and marketing releases, not clinical-trial protocols or peer‑reviewed trial results [1] [2] [3] [4]. By contrast, major Alzheimer’s monoclonal antibody programs like aducanumab and lecanemab are widely known to have used amyloid biomarker reductions as central measures in their development — however, specific trial-by-trial endpoint lists are not provided in the available search results (available sources do not mention detailed endpoints for aducanumab/lecanemab in this set).
1. What the sources actually show about “Neurocept”
All search hits for “Neurocept” in the provided set point to consumer-facing product coverage, marketing releases and review articles presenting Neurocept as a brain‑health supplement or wellness product, not as a licensed therapeutic supported by randomized phase 2/3 trials with biomarker endpoints [1] [2] [3] [4]. These items emphasise ingredients, user testimonials and positioning within the cognitive‑wellness market rather than clinical trial methodology or use of PET/tau/CSF biomarkers as primary outcomes [1] [4] [3]. The available sources do not mention any Neurocept clinical trials, trial registration numbers, or primary endpoint definitions.
2. Why that distinction matters: supplements versus disease‑modifying trials
Peer‑reviewed drug development for Alzheimer’s disease typically frames primary endpoints around clinical outcomes (cognitive/functional scales) and increasingly uses biomarkers (amyloid PET, tau PET, CSF amyloid/tau, neurofilament light) for target engagement or secondary endpoints. The documents here show Neurocept is marketed as a supplement for “memory, focus, and cognitive health” and explicitly state it is not intended to treat or cure disease, which aligns with wellness positioning rather than a regulated disease‑modifying program [4] [3]. The sources do not say Neurocept conducted trials that would mimic the regulatory-style biomarker endpoint strategy seen in pharmaceutical development [1] [4].
3. What the available sources say about biomarkers in neurodegenerative research
Several items in the result set describe an active, growing field of fluid and imaging biomarkers — conferences, reviews and market reports discuss amyloid/tau imaging, CSF measures and neurofilament assays as tools for diagnosis, progression monitoring and therapeutic development [5] [6] [7] [8] [9]. These sources show the research and commercial ecosystems are emphasizing biomarkers, but they do not link Neurocept to any such trials or to using biomarkers as primary endpoints [5] [6] [7].
4. What we can and cannot conclude about aducanumab/lecanemab from these results
The provided set does not include primary-source trial protocols or regulatory summaries for aducanumab or lecanemab. Therefore, claims about whether those antibody programs used biomarkers as primary endpoints are not supported or contradicted by these particular search results; explicitly, available sources do not mention the endpoint details for aducanumab or lecanemab within this collection (available sources do not mention detailed endpoints for aducanumab/lecanemab in this set). Separate primary sources would be needed to compare endpoint strategies directly.
5. Alternative viewpoints and possible hidden agendas
Marketing and press pieces about Neurocept aim to sell a consumer product and emphasise “science-backed” language and testimonials; that creates a credibility halo but does not substitute for trial evidence [1] [3] [4]. Conference and review material on biomarkers reflect an industry and academic agenda to validate and commercialize biomarker assays — those stakeholders benefit from broader biomarker adoption in trials and diagnostics [5] [6] [7]. The juxtaposition of supplement marketing and biomarker‑driven drug development can mislead non‑expert audiences into conflating consumer health claims with regulated therapeutic evidence.
6. Bottom line and what to check next
Based on the available reporting, Neurocept is presented as a consumer brain‑health supplement with no documented clinical trials using amyloid PET, tau PET or CSF biomarkers as primary endpoints in these sources [1] [2] [4] [3]. To answer your original comparative question definitively, obtain primary trial documents or regulatory filings for each program: clinicaltrial.gov listings or peer‑reviewed trial publications for aducanumab, lecanemab and any Neurocept clinical program; and trial protocols or labeling that state which endpoints were primary versus secondary (available sources do not mention such trial documents for Neurocept here).